Beyond the West: How Japan and South Korea are Shaping the Next Era of Clinical Development
As the pharma industry looks beyond the West, Japan and Korea are emerging as premier destinations for clinical trials. Their advanced medical facilities, regulatory efficiencies, and thriving research environments make them ideal for drug development. But what truly sets them apart? With insights from Yoshihito Kondo, Partner, Consulting and Navigation Unit, CMIC Holdings, and Hyesook (Aviva) Park, Executive Director and Head of CMIC South Korea, download this whitepaper to explore:
- The biggest unmet needs in Japan & Korea and how pharma can address them
- Study start-up and approval time comparisons vs. the U.S.
- How these countries’ infrastructure is accelerating clinical breakthroughs
- The competitive edge of running trials in Japan & Korea
- And much more
Published March 2025
